Apogem Capital’s Cymabay Therapeutics CBAY Stock Holding History

Apogem Capital’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,924	Closed	-$44K	–	200
2021 Q4	$44K	Buy	+12,924	New	+$49.1K	0.03%	170

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Apogem Capital's CBAY Position: Q1 2022 in Review

Apogem Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2022, closing a stake of 12,924 shares — an estimated $44K sold.

Apogem Capital first reported a position in CBAY in Q4 2021 and held it in 1 quarter. The position peaked at $44K in Q4 2021. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

Apogem Capital reported no remaining Cymabay Therapeutics position as of Q1 2022 after selling out during the quarter.
Apogem Capital sold 12,924 Cymabay Therapeutics shares in Q1 2022, an estimated $44K.
Apogem Capital first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 1 quarter.
Apogem Capital's Cymabay Therapeutics position peaked at $44K in Q4 2021.
118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Apogem Capital's 13F filing for Q1 2022, filed 16 May 2022.